Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta‐analysis of randomized controlled trials
Iannone A, Natale P, Palmer SC, et al.
Diabetes Obes Metab. 2023;25(9):2535-2544.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Glycaemic control, risk of hypoglycaemia and all-cause mortality in new users of second-generation basal insulin with type 2 diabetes and chronic kidney disease: a nationwide register-based cohort study
Kosjerina V, Carstensen B, Amadid H, Vistisen D
Diabetologia. Pub. online 28 Jul 2023.
Leggi
Associations of lipoprotein subclasses with risk of all‐cause and cardiovascular disease mortality in individuals with type 2 diabetes: A prospective cohort study
Li R, Chen JX, Lu Q, et al.
Diabetes Obes Metab. Pub. online 26 Jul 2023.
Leggi
Adaptive bolus calculators for people with type 1 diabetes: A systematic review
Unsworth R, Avari P, Lett AM, et al.
Diabetes Obes Metab. Pub. online 24 Jul 2023.
Leggi
Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes
Park S, Jeong HE, Bea S, et al.
Diabetes Obes Metab. Pub. online 28 Jul 2023.
Leggi
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
Neves JS, Borges-Canha M, Vasques-Nóvoa F, et al.
J Am Coll Cardiol. 2023;82 (6) 517–525.
Leggi
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Balasubramanian P, Kernan WN, Sheth KN, et al.
Stroke. 2023;54(8):2013-2021.
Leggi
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
Xie Y, Bowe B, Xian H, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00171-7.
Leggi
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists
Alhiary R, Kesselheim AS, Gabriele S, et al.
JAMA. Pub. online 28 Jul 2023.
Leggi
Evaluation of insulin pump infusion sites in type 1 diabetes: the DERMIS study
Kalus A; Shinohara MM, Wang R, et al.
Diabetes Care. 2023 Jul 14;dc230426.
Leggi